13420-58-1

Usage

Compound structure

2-(3-chlorophenylthio)benzoic acid consists of a benzoic acid molecule attached to a 3-chlorophenylthio group.

Usage

Commonly used as a precursor in the synthesis of various pharmaceutical and agricultural products.

Enzyme inhibition

Known for its ability to inhibit the production of certain enzymes, such as cyclooxygenase-2, which play a role in inflammation and pain.

Anti-cancer properties

Has been studied for its potential anti-cancer properties, as it has been found to inhibit the growth of certain types of cancer cells.

Chemical structure importance

Its chemical structure and properties make it a valuable compound in various fields of research and industry.

InChI:InChI=1/C13H9ClO2S/c14-9-4-3-5-10(8-9)17-12-7-2-1-6-11(12)13(15)16/h1-8H,(H,15,16)

Upstream product

• 2037-31-2 3-chlorophenylthiol 
• 88-67-5 2-Iodobenzoic acid 
• 108-37-2 1-bromo-3-chlorobenzene 
• 147-93-3 Thiosalicylic acid 

Downstream Products

• 38605-72-0 1-chlorothioxanthen-9-one 
• 107623-98-3 methyl 2-(3-chlorophenylsulfanyl)benzoate 
• 108476-40-0 2-(3-chloro-phenylsulfanyl)-benzoic acid ethyl ester 
• 13420-59-2 [2-(3-Chloro-phenylsulfanyl)-phenyl]-methanol 
• 13420-60-5 C₁₃H₁₀Cl₂S 
• 13420-62-7 [2-(3-Chloro-phenylsulfanyl)-phenyl]-acetic acid 
• 13420-61-6 [2-(3-Chloro-phenylsulfanyl)-phenyl]-acetonitrile 
• 6469-87-0 3-chloro-9H-thioxanthen-9-one 

Relevant academic research and scientific papers

Triplet decay-induced negative temperature dependence of the transient photoluminescence decay of thermally activated delayed fluorescence emitter

The photophysical properties of three TX-based D-A isomers (TXO-PhCz1, TXO-PhCz3, and TXO-PhCz4) with a PhCz donor at different substitution positions of phenyl group on a TXO unit were investigated. The substitution position of the PhCz unit significantly impacts the photophysical properties of these isomers. TXO-PhCz1 exhibits a very weak emission in both undoped and doped films, while TXO-PhCz3 and TXO-PhCz4 exhibit a strong emission with the requisite properties for TADF emitters, including a small ΔEST and transient PL decay curves with a prompt and delayed fluorescent component. TXO-PhCz4 exhibits a much stronger orbital coupling than TXO-PhCz3 and then the phosphorescent emission causes the inverse temperature dependence of the transient PL decay, which is contrary to that of TXO-PhCz3 and other TADF emitters. TXO-PhCz4 exhibits a small ΔEST of 23 meV and a short decay time of 14 μs at room temperature, which are much smaller and shorter than those of TXO-PhCz3. Multilayer OLEDs based on TXO-PhCz4 exhibit a very low-efficiency roll-off with a maximum current efficiency of 49.2 cd A-1, a maximum power efficiency of 47.7 lm W-1, and a maximum EQE of 16.3%.

Thioxanthenone antitumor agents

Compounds having anti-tumour activity are disclosed having the formulawherein: (1) n is 2 or 3;R1 and R2 are independently lower-alkyl;Q is a residue chosen from the group consisting ofCH2NHR3, CH2N(R4)SO2R7, CH2NHCHO, CH=N-Ar,C(O)NR5R6, CH2N(R4)C(O)R7, CH2N(C2H5)CHO,CH2N(R4)P(O)(O-lower-alkyl)2, CH2N=CH-N(R9)(R10),CH2N(R4)C(O)CF3 and CH2N(R4)C(O)OR7;R3 is hydrogen or lower-alkyl;R4 is hydrogen, lower-alkyl or Ar;R5 is hydrogen, lower-alkyl or Ar;R6 is hydrogen or lower-alkyl;R7 is lower-alkyl, or Ar;R8 is hydroxy;Ar is phenyl or phenyl substituted with methyl, methoxy, hydroxy, halogen or nitro; andR9 and R10 are independently lower-alkyl; or(2) Q is a residue chosen from the group consisting of CH2N(R4)SO2R7, CH=N-Ar, C(O)NR5R6, CH2N(R4)C(O)R7, CH2N(R4)P(O)(O-lower-alkyl)2, CH2N(R4)C(O)CF3 and CH2N(R4)C(O)OR7; R8 is hydrogen, lower-alkyl, lower-alkoxy, or hydroxy; Ar is phenyl substituted by hydroxy; and n, R1, R2, R4, R5, R6, and R7 are as defined hereinabove in part (1) with the proviso that one or more of R4, R5, or R7 is Ar; or(3) Q is a residue chosen from the group consisting of CH2N=CH-N(R9)(R10) and CH2N(R4)C(O)CF3 ; R8 is hydrogen, lower-alkyl, lower-alkoxy, or hydroxy; and n, R1, R2, R4, R7, Ar, R9 and R10 are as defined hereinabove in part (1), or a pharmaceutically acceptable acid-addition salt or solvate thereof . Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.

Lyophilized thioxanthenone antitumor agents

Disclosed are reconstituted lyophilized formulations for the treatment of mammalian tumors comprising a thioxanthenone antitumor agent in combination with mannitol or sucrose as a stabilizer in a lactate buffer.

Thioxanthenone antitumor agents

1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones are disclosed as antitumor agents. Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.